• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why CorMedix Shares Are Trading Higher By Over 19%; Here Are 20 Stocks Moving Premarket

    11/15/23 8:07:57 AM ET
    $AGIL
    $AIRE
    $ARCT
    $CRMD
    Professional Services
    Consumer Discretionary
    Real Estate
    Finance
    Get the next $AGIL alert in real time by email

    Shares of CorMedix Inc. (NASDAQ:CRMD) surged in pre-market trading as the company posted a narrower-than-expected third-quarter loss.

    Cormedix posted a loss of 17 cents per share for the third quarter, versus market expectations for a loss of 21 cents per share.

    CorMedix shares gained 19.3% to $3.74 in pre-market trading

    Here are some other stocks moving in today's pre-market trading.

    Gainers

    • Heart Test Laboratories, Inc. (NASDAQ:HSCS) shares rose 97.1% to $0.3545 in pre-market trading after jumping 16% on Tuesday.
    • AgileThought, Inc. (NASDAQ:AGIL) shares surged 74.1% to $0.1410 in pre-market trading.
    • MGO Global, Inc. (NASDAQ:MGOL) shares rose 43.4% to $0.7117 in pre-market trading after reporting a sharp rise in third-quarter sales.
    • Solid Biosciences Inc. (NASDAQ:SLDB) shares rose 27.7% to $2.72 in pre-market trading. Solid Biosciences announced IND clearance by the FDA for duchenne muscular dystrophy gene therapy candidate SGT-003.
    • GDEV Inc. (NASDAQ:GDEV) rose 24.7% to $3.38 in pre-market trading after falling 5% on Tuesday.
    • Next.e.GO N.V. (NASDAQ:EGOX) shares climbed 21.6% to $0.6526 in pre-market trading after jumping 16% on Tuesday.
    • MYT Netherlands Parent B.V. (NASDAQ:MYTE) rose 19.5% to $2.45 in pre-market trading after dipping 33% on Tuesday. Mytheresa is expected to release first quarter fiscal year 2024 financial results on Nov. 28, 2023
    • Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) shares rose 19.2% to $23.13 in pre-market trading after the company reported a narrower third-quarter loss.
    • Heron Therapeutics, Inc. (NASDAQ:HRTX) gained 15.2% to $0.6220 in pre-market trading after the company reported mixed third-quarter financial results and issued guidance.

    Losers

    • Marpai, Inc. (NASDAQ:MRAI) dipped 18.7% to $0.52 in pre-market trading. Marpai recently posted a narrower loss for the third quarter.
    • reAlpha Tech Corp. (NASDAQ:AIRE) shares fell 14.2% to $10.30 in pre-market trading after jumping around 104% on Tuesday. ReAlpha Tech Corp began trading on the Nasdaq under the symbol AIRE on Oct. 23 and is an early-stage company that develops and utilizes its artificial intelligence technology stack to enable retail investors to invest in short-term rental properties.
    • Tivic Health Systems, Inc. (NASDAQ:TIVC) shares fell 14.7% to $1.86 in pre-market trading following downbeat sales results for the third quarter.
    • Intrusion Inc. (NASDAQ:INTZ) shares fell 13.4% to $0.4586 in pre-market trading as the company reported downbeat third-quarter financial results.
    • Kidpik Corp. (NASDAQ:PIK) fell 12.3% to $0.40 in pre-market following weak sales for the third quarter.
    • Varex Imaging Corporation (NASDAQ:VREX) shares fell 10.9% to $17.30 in pre-market trading after the company reported worse-than-expected fourth-quarter revenue results and issued guidance.
    • Electriq Power Holdings, Inc. (NASDAQ:ELIQ) shares fell 10% to $0.7380 in pre-market trading following third-quarter results.
    • Peraso Inc. (NASDAQ:PRSO) fell 8.7% to $0.2101 in pre-market trading. Peraso recently posted upbeat quarterly results.
    • Top KingWin Ltd (NASDAQ:TCJH) shares fell 8.1% to $1.25 in pre-market trading.
    • Momentus Inc. (NASDAQ:MNTS) fell 6.1% to $3.37 in pre-market trading after reporting weak quarterly results.

    Now Read This: Investor Optimism Improves Following US Inflation Data

    Get the next $AGIL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGIL
    $AIRE
    $ARCT
    $CRMD

    CompanyDatePrice TargetRatingAnalyst
    Arcturus Therapeutics Holdings Inc.
    $ARCT
    1/23/2026$20.00Buy
    Roth Capital
    Solid Biosciences Inc.
    $SLDB
    12/4/2025$16.00Buy
    Needham
    reAlpha Tech Corp.
    $AIRE
    11/26/2025$2.00Buy
    H.C. Wainwright
    Arcturus Therapeutics Holdings Inc.
    $ARCT
    10/24/2025$12.00Buy → Neutral
    H.C. Wainwright
    Arcturus Therapeutics Holdings Inc.
    $ARCT
    10/23/2025$12.00Buy → Neutral
    Citigroup
    Arcturus Therapeutics Holdings Inc.
    $ARCT
    10/22/2025Buy → Neutral
    Guggenheim
    CorMedix Inc.
    $CRMD
    10/20/2025$14.00Hold → Buy
    D. Boral Capital
    Arcturus Therapeutics Holdings Inc.
    $ARCT
    9/4/2025$60.00Buy
    H.C. Wainwright
    More analyst ratings

    $AGIL
    $AIRE
    $ARCT
    $CRMD
    SEC Filings

    View All

    Tivic Health Systems Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

    3/13/26 5:27:44 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    reAlpha Tech Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - reAlpha Tech Corp. (0001859199) (Filer)

    3/12/26 8:46:02 AM ET
    $AIRE
    Real Estate
    Finance

    SEC Form 10-K filed by reAlpha Tech Corp.

    10-K - reAlpha Tech Corp. (0001859199) (Filer)

    3/12/26 8:31:19 AM ET
    $AIRE
    Real Estate
    Finance

    $AGIL
    $AIRE
    $ARCT
    $CRMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Scott Anthony bought $2,126 worth of shares (2,175 units at $0.98), increasing direct ownership by 0.34% to 638,793 units (SEC Form 4)

    4 - INTRUSION INC (0000736012) (Issuer)

    1/12/26 7:57:35 AM ET
    $INTZ
    Computer Communications Equipment
    Telecommunications

    Chief Financial Officer Pinson Kimberly bought $2,444 worth of shares (2,500 units at $0.98), increasing direct ownership by 4% to 61,154 units (SEC Form 4)

    4 - INTRUSION INC (0000736012) (Issuer)

    1/12/26 7:58:01 AM ET
    $INTZ
    Computer Communications Equipment
    Telecommunications

    Director Eitan Yaron bought $100,000 worth of shares (100,000 units at $1.00), increasing direct ownership by 10% to 1,089,073 units (SEC Form 4)

    4 - Marpai, Inc. (0001844392) (Issuer)

    11/12/25 6:50:17 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $AGIL
    $AIRE
    $ARCT
    $CRMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    reAlpha (NASDAQ: AIRE) Reports Fourth Quarter and Full Year 2025 Results; Record Full-Year Revenue of $4.5 Million, Up 376% Year Over Year

    DUBLIN, Ohio, March 12, 2026 (GLOBE NEWSWIRE) -- reAlpha Tech Corp. (NASDAQ:AIRE) (the "Company" or "reAlpha"), an AI-powered real estate technology company, today announced financial results for the quarter and full year ended December 31, 2025. Full Year Financial Highlights (All figures are approximate and compared to FY 2024 unless otherwise stated) Revenue increased 376% to $4.5 million, compared to $0.9 million in FY 2024. The increase was driven primarily by increased revenue from mortgage brokerage transactions from reAlpha Mortgage, subscription fees from AiChat's AI conversational technologies, and revenues generated from Prevu's real estate services following its acquisition

    3/12/26 8:35:00 AM ET
    $AIRE
    Real Estate
    Finance

    Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial

    - 40 participants have been dosed with SGT-003 in the INSPIRE DUCHENNE trial to date - - Robust microdystrophin expression with consistent mechanistic evidence of dystrophin associated protein complex (DAPC) restoration and improvements in muscle integrity, including stabilization and improvement in cardiac function (LVEF) observed after treatment with SGT-003 - - SGT-003 continued to demonstrate an encouraging safety profile and has been generally well tolerated in the 40 participants dosed as of March 11, 2026 - - SGT-003 is administered using a lower-burden, steroid-only prophylactic immunomodulation regimen - - The Company plans for additional meetings with the FDA in H1 2026 for gui

    3/11/26 1:01:00 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Varex Management to Present in Upcoming Investor Conferences

    Varex Imaging Corporation (NASDAQ:VREX) announced today that management is scheduled to present at the following upcoming investor conferences. Oppenheimer's 36th Annual Healthcare, MedTech & Services Virtual Conference: Tuesday, March 17, 2025 at 10:40am ET. Webcast link here. Sidoti Small Cap Virtual Conference: Wednesday, March 18, 2026 at 1:00pm ET. Webcast link here. The webcast can be accessed at the above links or on Varex's website at http://www.vareximaging.com/news. About Varex Varex Imaging Corporation is a leading innovator, designer and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors and other image processing solutions that

    3/10/26 9:05:00 AM ET
    $VREX
    Industrial Machinery/Components
    Technology

    $AGIL
    $AIRE
    $ARCT
    $CRMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on Arcturus Therapeutics with a new price target

    Roth Capital initiated coverage of Arcturus Therapeutics with a rating of Buy and set a new price target of $20.00

    1/23/26 8:16:17 AM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham initiated coverage on Solid Biosciences with a new price target

    Needham initiated coverage of Solid Biosciences with a rating of Buy and set a new price target of $16.00

    12/4/25 8:48:04 AM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on reAlpha Tech Corp. with a new price target

    H.C. Wainwright initiated coverage of reAlpha Tech Corp. with a rating of Buy and set a new price target of $2.00

    11/26/25 8:37:18 AM ET
    $AIRE
    Real Estate
    Finance

    $AGIL
    $AIRE
    $ARCT
    $CRMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Perceptive Advisors Llc

    4 - Solid Biosciences Inc. (0001707502) (Issuer)

    3/11/26 4:00:03 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Antony Prabhu

    3 - reAlpha Tech Corp. (0001859199) (Issuer)

    3/6/26 5:25:14 PM ET
    $AIRE
    Real Estate
    Finance

    SEC Form 4 filed by Chief Technology Officer Schwarz Robert E

    4 - Momentus Inc. (0001781162) (Issuer)

    3/3/26 6:58:28 PM ET
    $MNTS
    Military/Government/Technical
    Industrials

    $AGIL
    $AIRE
    $ARCT
    $CRMD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZYNRELEF KIT issued to HERON THERAPS INC

    Submission status for HERON THERAPS INC's drug ZYNRELEF KIT (SUPPL-18) with active ingredient BUPIVACAINE; MELOXICAM has changed to 'Approval' on 11/21/2024. Application Category: NDA, Application Number: 211988, Application Classification: Labeling

    11/22/24 4:36:11 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for APONVIE issued to HERON THERAPS INC

    Submission status for HERON THERAPS INC's drug APONVIE (SUPPL-3) with active ingredient APREPITANT has changed to 'Approval' on 03/05/2024. Application Category: NDA, Application Number: 216457, Application Classification: Labeling

    3/11/24 4:38:31 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for CINVANTI issued to HERON THERAPS INC

    Submission status for HERON THERAPS INC's drug CINVANTI (SUPPL-15) with active ingredient APREPITANT has changed to 'Approval' on 03/05/2024. Application Category: NDA, Application Number: 209296, Application Classification: Labeling

    3/11/24 4:38:29 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIL
    $AIRE
    $ARCT
    $CRMD
    Leadership Updates

    Live Leadership Updates

    View All

    reAlpha Tech Corp. Appoints Thomas Kutzman as Chief Financial Officer to Support Growth Strategy

    DUBLIN, Ohio, Feb. 27, 2026 (GLOBE NEWSWIRE) -- reAlpha Tech Corp. (NASDAQ:AIRE) (the "Company" or "reAlpha"), an AI-powered real estate technology company, today announced the appointment of Thomas Kutzman as Chief Financial Officer, effective February 25, 2026. Mr. Kutzman succeeds Piyush Phadke and will oversee the Company's financial operations, capital strategy, and key corporate functions such as human resources and legal, reporting directly to Chief Executive Officer Mike Logozzo. Kutzman brings more than 12 years of financial markets experience to the role. Prior to co-founding Prevu, he held investment and trading roles at SAC Capital, JPMorgan, Citi, and Jabre Capital Partners,

    2/27/26 8:30:00 AM ET
    $AIRE
    Real Estate
    Finance

    reAlpha (NASDAQ: AIRE) Leadership to Join H.C. Wainwright "HCW @ Home" Virtual Fireside Chat

    DUBLIN, Ohio, Feb. 09, 2026 (GLOBE NEWSWIRE) -- reAlpha Tech Corp. (NASDAQ:AIRE) (the "Company" or "reAlpha"), an AI-powered real estate technology company, today announced its participation in a fireside chat with H.C. Wainwright titled: "HCW @ Home." The live, online session scheduled for Thursday, February 12, 2026 at 11:00 A.M. ET will feature Mike Logozzo, Chief Executive Officer, and Piyush Phadke, Chief Financial Officer. H.C. Wainwright's Scott Buck, Managing Director - Equity Research, Technology, will host the fireside chat, during which reAlpha's management will discuss the Company's business strategy and priorities for 2026, including the role of AI and M&A in scaling the Comp

    2/9/26 8:30:00 AM ET
    $AIRE
    Real Estate
    Finance

    MARPAI, INC. HIRES PHARMACY EXECUTIVE MIMI DAVIS AS PRESIDENT OF MARPAIRX TO DRIVE STRATEGIC GROWTH

    TAMPA, Fla., Jan. 27, 2026 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology, Pharmacy Benefit Management (PBM) and Third-Party Administration (TPA) services, announced the hiring of Mimi Davis as President of MarpaiRx. Davis, a distinguished leader in the pharmacy services sector, will oversee the strategic expansion and operational scaling of Marpai's pharmacy benefit offerings. Davis joins Marpai from Knipper Health, where she served as Executive Vice President of Operations. Her deep industry roots include a significant tenure at Eagle Pharmacy—a former HillCour portfolio company—which was acquired by Knipper in 2020. With

    1/27/26 8:23:00 AM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    $AGIL
    $AIRE
    $ARCT
    $CRMD
    Financials

    Live finance-specific insights

    View All

    reAlpha (NASDAQ: AIRE) Reports Fourth Quarter and Full Year 2025 Results; Record Full-Year Revenue of $4.5 Million, Up 376% Year Over Year

    DUBLIN, Ohio, March 12, 2026 (GLOBE NEWSWIRE) -- reAlpha Tech Corp. (NASDAQ:AIRE) (the "Company" or "reAlpha"), an AI-powered real estate technology company, today announced financial results for the quarter and full year ended December 31, 2025. Full Year Financial Highlights (All figures are approximate and compared to FY 2024 unless otherwise stated) Revenue increased 376% to $4.5 million, compared to $0.9 million in FY 2024. The increase was driven primarily by increased revenue from mortgage brokerage transactions from reAlpha Mortgage, subscription fees from AiChat's AI conversational technologies, and revenues generated from Prevu's real estate services following its acquisition

    3/12/26 8:35:00 AM ET
    $AIRE
    Real Estate
    Finance

    CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    ‒ Q4 2025 Net Revenue of $128.6 million ‒ ‒ Pro Forma Full Year 2025 Net Revenue of $401.3 million ‒   ‒ Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ PARSIPPANY, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the fourth quarter and full-year ended December 31, 2025 and provided an update on its business. Recent Corporate Highlights: CorMedix announces $128.6 million of net revenue for the fourth qu

    3/5/26 7:30:00 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress

    ARCT-032 (CF) Phase 2 third cohort (28 days, 15 mg) generally safe and well tolerated ARCT-032 permitted to proceed into 12-week Phase 2 study; dosing to begin H1 2026 Cash runway extended into Q2 2028 Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the fourth quarter and fiscal year 2025, and provided corporate updates. "Arcturus continues to progress its rare disease therapeutic portfolio. We look forward to aligning with regulators on our clinical d

    3/3/26 4:01:00 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIL
    $AIRE
    $ARCT
    $CRMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Marpai Inc.

    SC 13D/A - Marpai, Inc. (0001844392) (Subject)

    12/9/24 5:14:07 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13D/A filed by Solid Biosciences Inc.

    SC 13D/A - Solid Biosciences Inc. (0001707502) (Subject)

    11/14/24 7:59:25 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Momentus Inc.

    SC 13G/A - Momentus Inc. (0001781162) (Subject)

    11/14/24 5:14:58 PM ET
    $MNTS
    Military/Government/Technical
    Industrials